Search This Blog

Friday, July 12, 2019

SC Health Corporation Announces IPO Pricing

SC Health Corporation (“SC Health”) announced today the pricing of its initial public offering and committed capital raise of up to $222.5 million in the aggregate, comprised of a $150 million initial public offering (up to $172.5 million if the Underwriters (defined below) exercise their over-allotment option in full), plus $50 million in committed capital to complete an initial business combination. The initial public offering of 15,000,000 units priced at $10.00 per unit. SC Health has granted the Underwriters a 45-day option to purchase up to 2,250,000 additional units at the initial public offering price to cover over-allotments, if any. The units will be listed on the New York Stock Exchange (“NYSE”) in the United States and trade under the ticker symbol “SCPE.U” beginning July 12, 2019. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SCPE” and “SCPE WS,” respectively. The initial public offering is expected to close on July 16, 2019, subject to customary closing conditions.
Credit Suisse Securities (USA) LLC is acting as sole book running manager in the offering and I-Bankers Securities, Inc. is acting as co-manager (together, the “Underwriters”).
SC Health Group Limited has agreed to provide $50 million in the form of committed capital in a private placement to occur concurrently with SC Health’s initial business combination. SC Health intends to use the net proceeds of the initial public offering and forward purchase agreement for an initial business combination with a target with operations or prospects in the healthcare sector in the Asia Pacific region, which may be a platform in the Asia Pacific region or a global platform with a meaningful Asia Pacific growth thesis and to cover operating expenses and working capital requirements.
SC Health is a special purpose acquisition company formed by SC Health Group Limited, an affiliate of SIN Capital Group Pte. Ltd. (“SINCap”), for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. SINCap is a Pan-Asia multi-asset professional investment firm with a differentiated investment approach centered around several key tenets: a long-term investment horizon and close partnership with management; building platforms in under-invested but high growth industries; and employing an ‘‘Investor-Operator’’ model focused on comprehensive operational value-add.

Thursday, July 11, 2019

Steps Toward Healing Brain and Spinal Cord Injuries

Recently, researchers have investigated a nerve repair process that could potentially be activated to heal injuries to the brain and spinal cord. This discovery came from investigating an existing peripheral nerve regeneration pathway and applying similar concepts to central nervous system cells. This research team was led by Claire Jacob, Professor at Johannes Gutenberg University Mainz (JGU) and at the Swiss University of Fribourg. Their findings were published in a recent edition of Cell Reports.
Damaged peripheral nerves regenerate after an injury, allowing sensation and function to be retained. Axons, the long portions of neurons that send electrical signals, must regrow after such injuries to properly recover function.
“An injury in the peripheral nervous system quickly triggers the activation of a fascinating repair process that allows the injured nerve to regenerate and regain its function,” explains Claire Jacob, Head of Cellular Neurobiology at JGU. “There is no such repair process in the central nervous system, thus injuries often lead to permanent damage such as paraplegia.” Strategies to improve axon regeneration in the central nervous system must therefore be developed to enable healing.
Certain axons are covered in a protective, insulating layer known as myelin. This myelin sheath serves not only to protect the axon, but to increase the speed of signaling between nerves and their targets.
“Myelin is extremely important for the function of the entire nervous system, however it also hinders the repair process in case of an injury,” noted Jacob.
The myelin sheath is created by Schwann cells in the peripheral nervous system and oligodendrocytes in the central nervous system (the brain and spinal cord). One major difference between the two is that the Schwann cells have a unique repair process in response to axonal injury.

Action of the Schwann Cell

In the peripheral system, Schwann cells rapidly induce disintegration of injured axonal pieces into fragments. These fragments are ultimately digested either by Schwann cells or macrophages. Clearing these axon fragments after injury is essential in the repair process in the peripheral nervous system.

“Schwann cells can do everything,” noted Jacob. “We discovered that they not only digest myelin following injury, but they also induce the disintegration of the long axon segments that are separated from their cell bodies due to the injury.”
For this to occur, the Schwann cell forms small spheres of the protein actin. Actin spheres put pressure on the isolated segments of axons until they are fragmented. For the intact region of the axon to grow back, it is key that this targeted degradation of cell debris occurs. This axon must remain attached to the neuron’s cell body and regrow towards its target once more.
The researchers found that these injured axon fragments send a signal to the Schwann cells that initiates this actin sphere formation and axon disintegration. Jacob and her team noted that this process is extremely coordinated and sensitive, with disruptions causing impaired regeneration.

Action of the Oligodendrocyte

After carefully studying this process in the peripheral nervous system’s Schwann cells, the researchers shifted focus to the oligodendrocyte function in the central nervous system.
“After an injury, oligodendrocytes either die or remain apparently unresponsive,” explained Jacob.
Unlike the versatile Schwann cell, the oligodendrocyte lacks the ability to form actin spheres and disintegrate damaged axons. This is because these cells do not express vascular endothelial growth factor receptor 1 (VEGFR1) like the Schwann cells do. This receptor is needed for producing the actin spheres and is inherently crucial in axonal repair.
Jacob and colleagues decided to induce VEGFR1 expression in the oligodendrocytes to see if the cells would begin to act as the Schwann cells do. The team found that the oligodendrocytes began to produce the actin spheres and disintegrate damaged axon fragments in the same repair process as the Schwann cells.

Going Forward With this Work

They are now working to identify the biological pathways associated with myelin removal at the injury site in the central nervous system. This is the next step required for the full rebuilding of damaged neurons.
“We have discovered a pathway that accelerates myelin degradation in the peripheral nervous system and are now trying to determine whether this can also trigger myelin removal in the central nervous system,” concluded Claire Jacob.
View image on Twitter
unifrBiology@unifrBiology
 ðŸ—ž️ | First step to induce self-repair in the central nervous system. The research team led by Prof. Claire Jacob @uni_mainz@unifrBiology have been published in @CellReports . http://www.unifr.ch/webnews/content/40/attach/9991.pdf?&p=1 

Israeli medical aesthetics company InMode files for a $75 million US IPO

InMode Limited, which develops and markets minimally-invasive medical aesthetic products, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.
The Yokneam, Israel-based company was founded in 2008 and booked $110 million in sales for the 12 months ended March 31, 2019. It plans to list on the Nasdaq under the symbol INMD. Barclays and UBS Investment Bank are the joint bookrunners on the deal. No pricing terms were disclosed.

Biophytis boosts size of U.S. IPO

In a quick amendment to its registration filing from earlier this week, France’s Biophytis (BPTS) says it will now offer 15M shares (including 10M ordinary shares in the form of American Depositary Shares) through H.C. Wainwright.
That’s up from 13.1M ordinary shares, 8.75M of those in the form of ADS.
It still expects to price the offering at $7-$9/ADS (about €0.62-€0.80 per ordinary share). Yesterday, the last reported sale price of ordinary shares in Paris as €0.80, currently corresponding to a price of $8.98 per ADS.

New Insights into the Vagus Nerve Could Change the Way Diabetes is Treated

A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.
A research team helmed by Theodoros Zanos, head of the Neural & Data Science Lab, discovered how the vagus nerve relays signals from the periphery to the brain to help regulate glucose. Previous research has revealed that the vagus nerve, which connects to numerous organs throughout the body and communicates changes in the body to the brainstem, plays a role in regulating metabolism. However, how the vagus nerve did this was not understood. Zanos and his research team set out to identify the specific signals relayed from the periphery to the brain that responded to changes in glucose levels. And that was just what they did. Now, this discovery could have implications in revealing a new way to measure blood glucose levels in people. Zanos’ findings were published in the Springer Nature journal, Bioelectronic Medicine.

In a statement, Zanos said they believed that listening to and stimulating the vagus nerve would open new possibilities to the diagnosis and management of various diseases.
“The vagus nerve is one of the major information conduits of the body with an average of 100,000 nerve fibers, making this code difficult to pick up and decipher, so we have a lot to learn,” Zanos said. “We’re excited to demonstrate in this most recent study that the vagus nerve of a mouse transports important signals from the periphery to the central nervous system related to glucose homeostasis – this discovery gets us closer to new technologies that will have the potential of helping many patients living with various metabolic diseases.”
In addition to serving as a highway for sensory information from organs to the brain, the vagus nerve also plays a role in regulating the heart rate and keeping the gastrointestinal tract in working order.
Feinstein Institutes President and Chief Executive Officer Kevin J. Tracey was a co-author of the paper, “Identification of hypoglycemia-specific neural signals by decoding murine vagus nerve activity.” The discovery made by Zanos and his team, Tracey said, “gives us new understanding of the body’s neural signaling and offers hope for diabetes management.”

This was not the first discovery that Zanos and his team have made with a potential to change the way a disease is treated. Last year, Zanos and team were the first to decode specific signals the nervous system uses to communicate immune status and inflammation to the brain. The identification of these neural signals and their role in the body’s health was a step forward in bioelectronic medicine, the Institute said. It provides provided insight into diagnostic and therapeutic targets, and device development. Bioelectronic medicine is a new approach to treating and diagnosing disease and injury that has sprung from the Feinstein Institutes’ labs. It uses new technology to read and modulate the electrical activity within the body’s nervous system, opening new doors to real-time diagnostics and treatment options for patients, the Feinstein Institute explained.

The Wild West of Anti-Aging Medicine

In a remote fishing lodge in Soldotna, Alaska—a town of just over 4000 people along 2 million pristine acres of protected wilderness—Dr Robert Ledda leads a specialized medical practice designed to help his patients manage or even optimize aging. People travel here with a wish list that seems endless: more energy, less stress, a sharper brain, a stronger libido, a healthier heart, more resilient muscles and bones, a better immune system, a more youthful appearance.
The problem with “mainstream medicine,” says Ledda, is that it’s disease-oriented and reactive, not preventive: That is, nurses and physicians see patients when they’re sick, not sooner.
“They don’t have the time,” says Ledda, a partner with Cenegenics Alaska, a branch of Cenegenics Medical Institute. Most doctors can’t spend 8 hours the first time they see a patient, as he does, evaluating activity levels, family history, stress, and eating habits. “They know that the vast majority of people are not going to change the way they live, so their tool bag is strictly disease-model and medication-based.”
In its marketing materials online and on social media, Cenegenics claims its elite, pricey program—or “healthy aging plan”—will “reverse the declines of aging and protect your future health.” Cenegenics clinics worldwide offer the same promise, from Boston to Columbus, Ohio, to Karnataka, India.
Physicians who specialize in so-called anti-aging medicine have long operated on the outskirts of the medical profession, and they draw their share of criticism, particularly for prescribing hormone therapy.
On a website called HGH Watch, longevity expert Thomas Perls, MD, MPH, characterizes the prescribing of human growth hormone (HGH) for anti-aging as “quackery and hucksterism.” Perls, a professor of medicine at the Boston University School of Medicine, also writes that hormone replacement therapy“and the drugs used to treat their side effects end up being hormonal toxic soups that can cause great medical and financial harm that far outweighs any long-term benefit.”
But as physicians brace for growing numbers of aging patients who hope to live longer and have a better quality of life in their older years with less disease, some treatments previously waved off as too emerging, expensive, or even vain are slowly becoming more accepted. The idea is that aging is inevitable, yes, but it’s also treatable—and even somewhat preventable.
“There’s way more scientists who are coming around [and] agree with our approach of primary prevention,” says Ledda, whose certification in age management medicine is a credential that is not recognized by mainstream medicine.
Still, the ranks of doctors who practice anti-aging and age management medicine are growing. The American Academy of Anti-Aging Medicine—which states its mission is to support research and technology that will “detect, treat, and prevent diseases associated with aging,” as well as treatments “designed to prolong the human life span” and “optimize the human aging process”—now has over 26,000 members. Of these, 85% are physicians and 12% are researchers, scientists, and “health practitioners.” (The remaining 3% is a mix of people, including members of the public.)

‘Specializing’ Without a Specialty

The question is, are these interventions that claim to combat the effects of aging based in science? Critics argue that the anecdotes and testimonials don’t pass the rigorous standards set by evidence-based medicine. Without clinical trials, the purported effects aren’t measurable or proven by legitimate science.
“Most of traditional medicine has taken a negative stance, I would say, against these [anti-aging interventions] because again, does it work? And is it safe? We can’t answer those questions,” says Dr Cynthia Stuenkel, a clinical professor of medicine at the University of California, San Diego, who published a warning about compounded bioidentical hormone therapy in JAMA Internal Medicine in 2017. Stuenkel also chaired the Endocrine Society’s treatment guidelines for menopause in November 2015.
The American Board of Medical Specialties (ABMS) does not certify a specialty or subspecialty for anti-aging. “[Our] process to establish a new specialty or subspecialty is rigorous and thoughtful,” ABMS said in a statement. “It involves input from internal and external stakeholders, public comment, committee review, and is ultimately an ABMS Board decision.” To qualify as a specialty, the area of medicine must focus on a “distinct and definable” group of patients, a “definable type of care need,” a “stand-alone” set of medical knowledge, or “unique care principles,” as well as “clearly demonstrating its value in improving access, quality, and coordination of care.”
“I’m not worried about them infiltrating legitimate medicine,” says S. Jay Olshansky, PhD, a gerontology professor at the University of Illinois at Chicago School of Public Health.
“The fact that there is no medical specialty called ‘anti-aging medicine’ is all that you need to know,” Olshansky says. “This has been the case from day one. Nothing’s changed.” On the other hand, he applauds the efforts of “anti-aging” doctors who encourage their patients to adopt a healthier lifestyle.
“Does that modulate some of the effects of aging? Yes, of course,” he says. “If you exercise, eat right, and lose weight, chances are you’re going to feel better, and you’ll probably live healthier for a longer time period. So if that’s what you’re doing, and you’re calling yourself an anti-aging doctor, then there’s a legitimate element to what you’re doing.”

Focusing on Prevention

Robert Ledda, MD
With the exception of one crucial component of his practice—prescribing hormones—Ledda’s strategy for his patients is largely preventive, beginning with a $2500 evaluation day that generates a baseline report. Then, patients begin a program of consistent exercise, a low-glycemic diet, hormone manipulation, and a handful of daily supplements. The first annual visit costs $2495, and subsequent check-ups are $1995. The monthly program fee in the first year is $350, plus the costs of the supplements, hormones, and lab work.
Ledda shares the story of his aunt, Pam, who hadn’t seen a doctor in 3 years when she first visited his practice. The “before” photo on his clinic’s Facebook page shows a 60-year-old woman with a sweet smile and a mix of gray and golden brown hair. The scale told a different story: At 209 pounds, she was morbidly obese.
“You go to a regular disease-model doctor, you’re going out the door on a blood pressure medicine, a cholesterol medicine, and a diabetes medicine,” Ledda says he remembers thinking after reviewing her first set of lab work. “The disease-model recipe was to start insulin. So we’re talking real disease here.”
Gradually, Pam began to feel motivated to change. She started attending Ledda’s lecture series, and she also worked with Ledda’s low-glycemic (“paleo”) chef for a week to learn how to cook.
One motivator that works for many patients is fear, Ledda says. “I can create some fear that’s a little more concrete than, Someday I may have problems, but right now I just want to eat the cake. The challenge with every patient is really getting a hold of their psyche to the point where they realize they just can’t keep doing that.”
That fear transformed his aunt’s life, he says: She changed what she ate and began exercising in a CrossFit gym 3 days per week, and she lost a significant amount of weight. Now, she is more fit and feels better. “She’s had improvements subjectively in every domain you could think of, and all of her numbers are great. Her systemic inflammation went away,” Ledda says. In her “after” photo posted on Facebook, she is far thinner, in workout gear: a beige hoodie, sneakers, and tight black leggings. She’s standing with a pal outside a big wall emblazoned with graffiti, with a wide, confident smile.
Though Ledda says he put her on some “conventional meds” for high cholesterol and diabetes after her initial visit, he has now “taken her off almost everything”; now, “she has no metabolic disease at all,” no diabetes, and her “cholesterol panel is immaculate on no medicines.”
At her first visit, Pam’s total cholesterol was 280 mg/dL; her bad cholesterol was 200, and her good cholesterol was quite low, in the 30s. Ledda attributes the transformation to a handful of things working together: diet, supplements, lifestyle changes, and weight loss. Now, she takes 500 mg of metformin daily, as well as a number of nutritional supplements. She’s also on hormone replacement therapy.

Changing the Hormonal ‘Soup’

Perhaps the most controversial element of the Cenegenics program is its focus on manipulating hormones in the aging body.
The regimen for women can include potentially dangerous bioidentical compounds, whereas men may be offered testosterone HGH, which has not approved by the US Food and Drug Administration (FDA) for anti-aging purposes. HGH has only been cleared for use in patients with HIV and for a rare condition in children called “adult growth hormone deficiency,” a diagnosis that has proved to be popular among anti-aging doctors.
Women who experience early or surgical menopause typically experience poorer cardiovascular, bone-density, and cognitive outcomes, as well as an increased risk of developing diabetes, Ledda says, which is why they are advised to undergo hormone replacement therapy. It can help most women who go through menopause.
“Why not continue them longer to continue to get those obvious benefits that science suggests are there?” he asks.
The Endocrine Society has come out against the use of HGH except in patients with clearly defined evidence of a growth hormone deficiency, Stuenkel says—for example, if they had a pituitary tumor or hypothalamic dysfunction. Another hormone to watch out for, she adds, is dehydroepiandrosterone (DHEA), an adrenal androgen male hormone. It’s controversial because of the lack of good evidence supporting its use.

New Use for an Old Drug?

One potentially promising drug that has already been tested in millions of patients is metformin, a diabetes medication that some of Ledda’s patients—including his aunt Pam—take to manage insulin resistance. “Ultimately, over many years of studying with tens of thousands of patients, we will learn if those people are healthier for longer—and then, we’ll have our first evidence that we’re on the right path,” says David Sinclair, a longevity researcher at Harvard who serves as an advisor for several biotech projects.
Patients who have taken the drug have less cancer, less heart disease, and less frailty than the average population, an effect that is “firmly based in science,” Sinclair says. “But because aging isn’t considered a disease, and you’re not diabetic until you actually have high blood sugar, you can’t easily get metformin as a preventive measure,” he adds.
The next step, Sinclair says, is securing funding to launch a massive study to test its safety and efficacy: the Targeting Aging with Metformin (TAME) trial, led by Albert Einstein College of Medicine’s Dr Nir Barzilai, who previously conducted the Metformin in Longevity (MILES) study. The National Institutes of Health rejected its grant proposal last fall, but if the trial gets off the ground, researchers will follow 3000 patients who are between 65 and 79 years old. The trial has support from the American Federation for Aging Research, and researchers hope it will show the FDA that aging can be slowed, and therefore can be treated as a medical condition, Sinclair says.
“Metformin could be the first drug that would be given to people in their 50s and 60s before they get sick, whereas now we wait until it’s too late.”
In the meantime, experts such as gerontology professor Olshansky remain skeptical about doctors promising to turn back the clock with “anti-aging” treatments that have not been proven effective.
“Mainstream medicine has not accepted this premise,” he says.

Doubled Risk of Death After Minimally Invasive Surgery for Cervical Cancer

Another blow has been dealt for minimally invasive surgery (MIS) in patients with cervical cancer — this time by Canadian researchers.
They report a population cohort study, which they say better reflects ‘the real world impact’ of such surgery. Their review of nearly 1000 patients with early stage cervical cancer found a twofold higher risk of death and cancer recurrence in those who underwent minimally invasive surgery (MIS) compared with those who had an open radical hysterectomy. The finding held even after controlling for surgeon volume.
The study was published online July 6 in the American Journal of Obstetrics and Gynecology.
The new findings echo those reported last year from two studies published in the New England Journal of Medicine.
“Rather surprisingly, and some would say shockingly, both studies showed a significant inferior survival associated with the use of the minimally invasive procedures,” Maurie Markman, MD, from Cancer Treatment Centers of America in Philadelphia, commented at the time.
The data from the two studies “have shown rather convincingly — and I would say definitively — that these minimally invasive procedures should not be performed, except under perhaps extraordinary circumstances where there is a serious risk for the patient associated with the standard approach,” he said.
Now, with the newly published Canadian findings, Markman is even more convinced that there are real dangers in using a minimally invasive approach in the treatment of cervical cancer.
“These disturbing data…again emphasize the critical need for well-designed and well-controlled clinical trials before a ‘novel surgical approach’ should be accepted as standard-of-care in cancer management,” he told Medscape Medical News in an email.
Monica Bertagnolli, MD, chief of surgical oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, and president of the American Society of Clinical Oncology, told Medscape Medical News recently that the results showing inferior oncologic outcomes after minimally invasive surgery in cervical cancer are “very very sobering.”
In general, more rigorous studies of minimally invasive cancer surgery are needed. What is most important, said Bertagnolli emphatically, is cancer outcomes — and not short-term benefits.
The Food and Drug Administration (FDA) has also expressed concern. In February, the agency issued a ‘caution’ about the use of robotically-assisted surgical devices in women’s health, and this included minimally invasive surgery for cervical and breast cancer.
The agency urged caution about any such use, noting that robotic devices are approved for use in prostate cancer but not in most cancers.

Advantages of Minimally Invasive Approach?

Arguments in favor of the minimally invasive approach include a shorter postoperative hospital stay, fewer complications, and smaller incisions, resulting in quicker recovery time and improved patient satisfaction compared with open surgery.
However, as one Medscape reader working in Ob/Gyn and women’s health commented: “I would suggest that the protocol of minimally invasive radical hysterectomy has benefited the bottom line of hospitals and insurance providers.
“I challenge all gynecologists to search for any protocol change that financially benefits hospitals and insurance companies that has truly benefited the patient,” the reader wrote in the comment section of the Markman article.
Another clinician in women’s health commented in agreement: “Well, finally, someone who has the good sense to state the obvious. Minimally invasive surgery for cancer has as its main beneficiaries the health insurance industry (reduced length of stay) and the companies that manufacture all that wonderfully expensive equipment used for the procedure, not the patient whose survival time is not a factor in revenue to the medical system.”

New Data From Canada

The new data from Canada come from a population-based retrospective cohort study of patients with cervical cancer who underwent a primary radical hysterectomy by a gynecologic oncologist from 2006–2017 in Ontario.
The team identified 958 women,958 women (mean age, 45.9 years) with predominantly stage 1B cervical cancer who underwent radical hysterectomy within 9 months of their diagnosis.
Open radical hysterectomy was done in half of the cohort; in the other half, 90% of the minimally invasive procedures were performed laparoscopically.
Patients undergoing minimally invasive radical hysterectomy were less likely to have high-risk features and fewer comorbidities than women who underwent open radical hysterectomy, the researchers note.
At a median follow-up of 6 years, “minimally invasive radical hysterectomy was associated with a two-fold higher rate of all-cause death and recurrence compared to open radical hysterectomy in patients with stage 1B disease, but not 1A or 2+ disease,” Maria Cusimano, MD, from the University of Toronto, and colleagues report.
This relationship held even after adjusting for patient factors as well as surgeon volume, they add.
The researchers note that, in contrast to the previously reported studies, “this population-based patient-level analysis reflects the real-world impact of minimally invasive radical hysterectomy, as performed by unselected surgeons on unselected early-stage cervical cancer patients,” the investigators write.
“Open hysterectomy should be the recommended approach in this population,” they conclude.

MIS Now Used in at Least Half of Cases

The new Canadian findings will undoubtedly fuel the argument that minimally invasive surgery is not as favorable as open radical hysterectomy in early cervical cancer — and this at a time when the proportion of early cervical cancer being treated with less invasive surgery is exploding.
For example, minimally invasive procedures accounted for more than half of all radical hysterectomies done for the treatment of cervical cancer in 2013, according to the authors of the National Cancer Database analysis that was published in the New England Journal of Medicine last year.
In the new Canadian cohort study, the proportion of cervical cancers treated using minimally invasive techniques — at least in the province of Ontario — climbed from 4.8% of all hysterectomies in 2006 to 65% in 2017.

Experts Caution Against It

Commenting on the National Cancer Database results last year in an accompanying NEJM editorial, Amanda Fader, MD, Johns Hopkins School of Medicine, Baltimore, Maryland suggested that select patient subgroups may still benefit from the less invasive approach. One example would be patients with tumors measuring less than 2 cm prior to surgery — for these types of patients, the outcomes were not worse with MIS in either of the two studies.
However, until it’s clear that the less invasive approach is equivalent to open hysterectomy in specific subgroups of patients, Fader urged surgeons to proceed with caution and to counsel their patients about these findings so that women are aware that there is a higher risk of recurrence with minimally invasive surgery than with open radical hysterectomy.
However, Markman in his Medscape commentary went a step further, and said that, at least from his perspective, minimally invasive radical hysterectomy should no longer be considered a standard-of-care for the treatment of early-stage cervical cancer.
In another commentary about the two studies, published earlier this year in the Journal of the National Comprehensive Cancer Network, Kathryn Pennington, MD, from the University of Washington Medicine in Seattle, and colleagues say that open radical hysterectomy and not a less invasive approach should now be considered standard-of-care for stage 1A2-1B1 cervical cancer.
Patients who still want to undergo less invasive surgery should be “guided appropriately”, they suggest, in order to make a more informed decision about which approach they would prefer their surgeon to take.
The Canadian authors have disclosed no relevant financial relationships. Markman has received grants from Genentech, AstraZeneca, Celgene, Clovis, and Amgen. Fader has received personal fees from Ethicon outside the submitted work. Pennington and Bertagnolli have disclosed no relevant financial relationships.
Am J Obstet Gynecol. Published online July 6, 2019. Full text